SGLT2 Inhibitors vs GLP-1 Agonists for Diabetes in Real-World Study

Compared with GLP-1 agonists, SGLT2 inhibitors were linked with similar cardiovascular outcomes but less heart failure, treatment discontinuation, healthcare use, and cost in a new study. Medscape Medical News

Read More

Leave a Reply

%d bloggers like this: